imatinib mesylate has been researched along with Growth Disorders in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 6 (54.55) | 24.3611 |
| 2020's | 3 (27.27) | 2.80 |
| Authors | Studies |
|---|---|
| Aggarwal, A; Bansal, D; Bhansali, A; Khandelwal, N; Sachdeva, N; Varma, N; Walia, R | 1 |
| Cai, Y; Chen, X; Chen, Y; Guo, Y; Liu, C; Yang, W; Zhang, L; Zhu, X; Zou, Y | 1 |
| Aimone, P; Allepuz, A; Bautista, F; Ducassou, S; Dufour, C; Goto, H; Guinipero, T; Hijiya, N; Kang, HJ; Karakas, Z; Maschan, A; Millot, F; Patterson, B; Rizzari, C; Samis, J; Shimada, H; Sosothikul, D; Titorenko, K; Yoo, KH; Zwaan, CM | 1 |
| Baruchel, A; Berthou, C; Bertrand, Y; Chastagner, P; Couillault, G; Galambrun, C; Gandemer, V; Guilhot, J; Khalifeh, T; Leblanc, T; Lutz, P; Mazingue, F; Millot, F; Petit, A; Reguerre, Y; Rialland, F; Vérité, C; Yacouben, K | 1 |
| Arts, FA; Chand, D; Constantinescu, S; Demoulin, JB; Hallberg, B; Pecquet, C; Velghe, AI | 1 |
| Jaeger, BA; Lohse, J; Schmid, H; Suttorp, M | 1 |
| Dewar, AL; Fitter, S; Hughes, TP; Menicanin, D; To, LB; Vandyke, K; Zannettino, AC | 1 |
| Hobernicht, SL; Hunger, SP; Schweiger, B; Wang, M; Zeitler, P | 1 |
| Hamamoto, K; Horibe, K; Hotta, N; Ito, M; Kato, K; Kurosawa, H; Muramatsu, H; Shima, H; Shimada, H; Tanizawa, A; Tokuyama, M; Tono, C; Tsurusawa, M; Watanabe, A | 1 |
| Blasdel, C; Boston, BA; Druker, B; Nguyen, T; Rastogi, MV; Stork, L | 1 |
| Bansal, D; Bhansali, A; Marwaha, RK; Narayanan, KR; Sachdeva, N; Varma, N; Walia, R | 1 |
2 trial(s) available for imatinib mesylate and Growth Disorders
| Article | Year |
|---|---|
A phase 2 study of nilotinib in pediatric patients with CML: long-term update on growth retardation and safety.
Topics: Child; Growth Disorders; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pyrimidines | 2021 |
Imatinib mesylate causes growth deceleration in pediatric patients with chronic myelogenous leukemia.
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Body Height; Body Mass Index; Child; Female; Growth Disorders; Humans; Imatinib Mesylate; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor I; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Retrospective Studies; Thyroid Hormones; Time Factors | 2012 |
9 other study(ies) available for imatinib mesylate and Growth Disorders
| Article | Year |
|---|---|
Acquired neuro-secretory defect in growth hormone secretion due to Imatinib mesylate and the efficacy of growth hormone therapy in children with chronic myeloid leukemia.
Topics: Antineoplastic Agents; Child; Child, Preschool; Female; Growth Disorders; Human Growth Hormone; Humans; Imatinib Mesylate; Insulin-Like Growth Factor I; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male | 2020 |
Long-term safety and efficacy of imatinib in pediatric patients with chronic myeloid leukemia: single-center experience from China.
Topics: Abnormal Karyotype; Adolescent; Anorexia; Antineoplastic Agents; Child; Child, Preschool; China; Drug Evaluation; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Growth Disorders; Humans; Imatinib Mesylate; Infant; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Male; Musculoskeletal Diseases; Progression-Free Survival; Protein Kinase Inhibitors; Remission Induction; Retrospective Studies; Treatment Outcome | 2021 |
Growth deceleration in children treated with imatinib for chronic myeloid leukaemia.
Topics: Adolescent; Antineoplastic Agents; Benzamides; Body Height; Body Mass Index; Child; Child, Preschool; Female; Growth Disorders; Humans; Imatinib Mesylate; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Retrospective Studies | 2014 |
PDGFRB mutants found in patients with familial infantile myofibromatosis or overgrowth syndrome are oncogenic and sensitive to imatinib.
Topics: Animals; Blotting, Western; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Female; Growth Disorders; Humans; Imatinib Mesylate; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Knockout; Mutagenesis, Site-Directed; Mutation; Myofibromatosis; Neoplasms, Experimental; NIH 3T3 Cells; Oncogenes; Protein Kinase Inhibitors; Receptor, Platelet-Derived Growth Factor beta; Syndrome | 2016 |
Longitudinal growth retardation in a prepuberal girl with chronic myeloid leukemia on long-term treatment with imatinib.
Topics: Benzamides; Child; Female; Growth Disorders; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2009 |
Imatinib mesylate causes growth plate closure in vivo.
Topics: Animals; Antineoplastic Agents; Benzamides; Child; Female; Growth Disorders; Growth Plate; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Rats; Rats, Sprague-Dawley | 2009 |
Acquired growth hormone deficiency in a girl with chronic myelogenous leukemia treated with tyrosine kinase inhibitor therapy.
Topics: Benzamides; Child; Dasatinib; Diseases in Twins; Female; Growth Disorders; Human Growth Hormone; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2011 |
Distinct impact of imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia.
Topics: Adolescent; Antineoplastic Agents; Benzamides; Body Height; Child; Child, Preschool; Female; Follow-Up Studies; Growth Disorders; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Puberty; Pyrimidines; Retrospective Studies | 2011 |
Growth failure in children with chronic myeloid leukemia receiving imatinib is due to disruption of GH/IGF-1 axis.
Topics: Adolescent; Anthropometry; Antineoplastic Agents; Benzamides; Child; Child, Preschool; Cross-Sectional Studies; Female; Growth Disorders; Human Growth Hormone; Humans; Imatinib Mesylate; Insulin-Like Growth Factor I; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines | 2013 |